BioSpace News Archive

RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced that Brian Wong, M.D., Ph.D., its President and CEO, will present a corporate update and company overview at the 38th Annual J.P. Morgan Healthcare Conference

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today outlined key clinical and business priorities for 2020.

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has converted approximately $1.8 million in debt investment from long-term private investors into its recent Preferred Equity transaction, bringing the cumulative total sold in this round to $7.8 million.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has been Certified by the National Association of College Stores (“NACS”), as a Vendor Affiliate (“Vendor”).

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020, at 4:00 p.m. Pacific Time.

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced an expansion in the development of rilzabrutinib (PRN1008) into IgG4-Related Disease (RD).

Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline® Autogel® (lanreotide injection) 60, 90, and 120 mg

Centene Corporation issued a reminder that it will release its 2019 fourth quarter and full year financial results at approximately 6 a.m. on Tuesday, February 4th, 2020, and host a conference call afterwards at approximately 8:30 a.m. to review the results.

VectivBio, a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases, today announced its formation with $35 million in financing including commitments by Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments.

Company’s Practices Oversee Care for the Complex, Chronically Ill Patients in National CMS Demonstration